Duloxetine: A review of its pharmacology and use in chronic pain management

Regional Anesthesia and Pain Medicine

Volumn 35, Issue 3, 2010, Pages 294-303

  Bellingham, Geoff A ^a,b   Peng, Philip W H ^a,b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CODEINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PLACEBO; PREGABALIN; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN;

ANALGESIA; APPETITE; BINDING AFFINITY; CARDIOMYOPATHY; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG WITHDRAWAL; FATIGUE; FIBROMYALGIA; HEADACHE; HEART FAILURE; HUMAN; HYPONATREMIA; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; LOEFFLER PNEUMONIA; MAJOR DEPRESSION; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOARTHRITIS; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; SWEATING; VOMITING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS, NON-NARCOTIC; ANTIDEPRESSIVE AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; HEADACHE; HUMANS; NEURALGIA; OSTEOARTHRITIS; PAIN; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 77952328473     PISSN: 10987339     EISSN: None     Source Type: Journal    
DOI: 10.1097/AAP.0b013e3181df2645     Document Type: Review

References (82)

1. Iskedijan M, Einarson TR, Walker JH, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251.
2. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81: S12-S25.
3. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153-1169.
4. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the canadian pain society. Pain Res Manag. 2007;12:13-21.
5. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci. 2002;25:319-325.
6. Millan MJ. Descending control of pain. Prog Neurobiol. 2002;66:355-474.
7. Pertovaara A. Noradrenergic pain modulation. Prog Neurobiol. 2006;80:53-83.
8. Iyengar S, Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther. 2004;311:576-584.
9. Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther. 2005;312:726-732.
10. Jones CK, Peters SC, Shannon HE. Synergistic interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the non-steroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents. Eur J Pain. 2007;11:208-215.
11. Joshi SK, Hernandez G, Mikusa JP, et al. Comparison of antinociceptive actions of standard analgesics in attenuating capsaicin and nerve-injury-induced mechanical hypersensitivity. Neuroscience. 2006;143:587-596.
12. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. 2005;48:252-263.
13. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109-118.
14. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346-356.
15. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-1420.
16. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res. 2005;39:43-53.
17. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry. 2007;68:1707-1716.
18. Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:2974-2984.
19. Arnold LM, Rosen A, Pritchett YL, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119:5-15.
20. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432-444.
21. New drug for neuropathic pain. FDA Consumer. 2004;38:2.
22. Food and Drug Administration. NDA approval letter. Available at: http://www.fda.gov/cder/foi/appletter/2008/022148s000ltrpdf. Accessed March 1, 2009.
23. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11:1475-1493.
24. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:1142-1150.
25. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000;40:161-167.
26. Eli Lilly Canada Inc. CYMBALTA: Product Monograph. Toronto, Ontario, Canada: Eli Lilly Canada Inc; 2007.
27. Zerjav S, Tse G, Scott M J W. Review of duloxetine and venlafaxine in depression. CPJ. 2009;142:144-152.
28. Glueck CJ, Khalil Q, Winiarska M, Wang P. Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA. 2006;295:1517-1518.
29. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet. 2008;47:191-202.
30. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2003;73:170-177.
31. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993;8:23-33.
32. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25:871-880.
33. Kasamo K, Blier P, De Montigny C. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther. 1996;277:278-286.
34. Beique JC, Lavoie N, de Montigny C, Debonnel G. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998;349:129-132.
35. Koch S, Hemrick-Luecke SK, Thompson LK, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology. 2003;45:935-944.
36. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250-1256.
37. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
38. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med. 2000;32:305-316.
39. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol. 2004;19(suppl 1): S15-S19.
40. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002;36:106-132.
41. Whitmyer VG, Dunner DL, Kornstein SG, et al. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry. 2007;68:1921-1930.
42. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008;42:22-34.
43. Kajdasz DK, Iyengar S, Desaiah D, et al. Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther. 2007;29(suppl): 2536-2546.
44. Wernicke J, Pangallo B, Wang F, et al. Hepatic effects of duloxetine-I: non-clinical and clinical trial data. Curr Drug Saf. 2008;3:132-142.
45. Wernicke J, Acharya N, Strombom I, et al. Hepatic effects of duloxetine-II: spontaneous reports and epidemiology of hepatic events. Curr Drug Saf. 2008;3:143-153.
46. Strombom I, Wernicke JF, Seeger J, D'Souza DN, Acharya N. Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources. Curr Drug Saf. 2008;3:154-162.
47. McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol. 2008;4:281-285.
48. Wohlreich MM, Acharya N, Strombom I, et al. Answers to the most common questions about the hepatic safety profile of duloxetine. Postgrad Med. 2008;120:111-118.
49. Safety data on Cymbalta (duloxetine hydrochloride) Vhepatic effects. Available at: www.fda.gov/medwatch/SAFETY/2005/Cymbalta-DearHCP05OCT2005. FINALSIGNEDpdf. Accessed March 1, 2009.
50. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25:132-140.
51. Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30:437-455.
52. Zhang L, Chappell J, Gonzales CR, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol. 2007;49:146-153. (Pubitemid 46579948)
53. Janicak PG, Davis JM, Preskorn SH, et al. Treatment with antidepressants. In: Mitchell CW, Kairis LR, Glazer A, et al. Principles and Practice of Psychopharmacotherapy. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
54. Keegan MT, Brown DR, Rabinstein AA. Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs. Anesth Analg. 2006;103:1466-1468.
55. Strouse TB, Kerrihard TN, Forscher CA, Zakowski P. Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine. J Clin Psychopharmacol. 2006;26:681-683.
56. Bergman BR, Reynolds HR, Skolnick AH, Castillo D. A case of apical ballooning cardiomyopathy associated with duloxetine. Ann Intern Med. 2008;149:218-219.
57. Colucci VJ, Berry BD. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Ann Pharmacother. 2008;42:882-887.
58. Hanje AJ, Pell LJ, Votolato NA, Frankel WL, Kirkpatrick RB. Case report: fulminant hepatic failure involving duloxetine hydrochloride. Clin Gastroenterol Hepatol. 2006;4:912-917.
59. Dirks AC, van Hyfte DM. Recurrent hyponatremia after substitution of citalopram with duloxetine. J Clin Psychopharmacol. 2007;27:313.
60. Kruger S, Lindstaedt M. Duloxetine and hyponatremia: a report of 5 cases. J Clin Psychopharmacol. 2007;27:101-104.
61. Maramattom BV. Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion and seizures. Neurology. 2006;66:773-774.
62. Espeleta VJ, Moore WH, Kane PB, Baram D. Eosinophilic pneumonia due to duloxetine. Chest. 2007;131:901-903.
63. Oulis P, Masdrakis VG, Karakatsanis NA, et al. Duloxetine-induced cutaneous adverse reaction. J Clin Psychopharmacol. 2008;28:104-105.
64. Loper T, Touchet B. An acute attack of porphyria in a patient taking duloxetine. Psychosomatics. 2007;48:179-180.
65. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol. 2008;8:29.
66. Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag. 2007;3:833-844.
67. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007; CD005454.
68. Quilici S, Chancellor J, Lothgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6.
69. Pritchett YL, McCarberg BH, Watkin JG, Robinson MJ. Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. Pain Med. 2007;8:397-409.
70. Russell IJ, Michalek JE, Vipraio GA, et al. Platelet 3 h-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol. 1992;19:104-109.
71. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum. 1992;35:550-556.
72. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol. 1992;19:90-94.
73. Schwarz MJ, Spath M, Muller-Bardorff H, et al. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett. 1999;259:196-198.
74. Hudson JI, Pope HG Jr. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am. 1996;22:285-303.
75. Sullivan MD, Bentley S, Fan MY, Gardner G. A single-blind, placebo run-in study of duloxetine for activity-limiting osteoarthritis pain. J Pain. 2009;10:208-213.
76. Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in parkinson disease. Clin Neuropharmacol. 2007;30:201-205.
77. Taylor AP, Adelman JU, Freeman MC. Efficacy of duloxetine as a migraine preventive medication: possible predictors of response in a retrospective chart review. Headache. 2007;47:1200-1203.
78. Volpe FM. An 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. J Clin Psychiatry. 2008;69:1449-1454.
79. Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U. S. patients with diabetic peripheral neuropathic pain. J Pain. 2006;7:399-407.
80. Overview of anticonvulsants, serotonin-norepinephrine reuptake inhibitors, and tricyclic antidepressants in management of neuropathic pain: a meta-analysis and economic evaluation. Technology Overview Number 49. Ottawa, Ontario: Canadian Agency for Drugs and Technologies in Health. Available at: www.cadth.ca/media/pdf/O0458-Management-of-Neuropathic-Pain-to-epdf. Accessed September 27, 2009.
81. O'Connor AB, Noyes K, Holloway RG. A cost-utility comparison of four first-line medications in painful diabetic neuropathy. Pharmacoeconomics. 2008;26:1045-1064.
82. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373:746-758.